Nevirapine Mylan

Nevirapine, the active ingredient in Nevirapine Mylan, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral dosage form for oral use. It is used to treat HIV‑1 infection as part of combination antiretroviral therapy in adults and adolescents.

GNH USA supplies Nevirapine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is a non‑nucleoside reverse transcriptase inhibitor indicated for HIV‑1 infection, where it helps suppress viral replication as part of combination therapy. - HIV‑1 infection: Used in combination antiretroviral regimens to reduce viral load and improve immune function.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: general feeling of tiredness. - Dizziness: occasional light‑headedness. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatotoxicity: liver enzyme elevations or hepatitis. - Severe hypersensitivity: including fever, malaise, and organ involvement. - Neutropenia: marked reduction in white blood cells. - Hepatic failure: rare but potentially life‑threatening liver dysfunction. - Anaphylaxis: acute allergic reaction with airway compromise.

Nevirapine requires careful monitoring due to its safety profile. - Liver monitoring: assess hepatic function before initiation and periodically during therapy. - Rash vigilance: discontinue if severe or progressive skin reactions develop. - Hypersensitivity: avoid in patients with known allergy to nevirapine or related compounds. - Pregnancy caution: use only if benefits outweigh potential risks, as safety data are limited. - Baseline CD4 count: evaluate immune status prior to starting therapy. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nevirapine interacts with several drugs that affect its metabolism.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that markedly reduces nevirapine plasma levels. - Carbamazepine: induces CYP enzymes, lowering nevirapine exposure. - Phenytoin: reduces nevirapine concentrations through hepatic induction.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may increase nevirapine levels, requiring dose adjustment. - Azole antifungals (e.g., fluconazole, ketoconazole): inhibit metabolism and can raise nevirapine concentrations. - St. John's wort: herbal inducer that may decrease nevirapine effectiveness.